

Amount in (Millions)																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																				
Related party transactions for the period 1 Oct 2024 to 31 Mar 2025														Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																						
Sr. No.	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Details of the loans, inter-corporate deposits, advances or investments																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																												
1	Lupin Limited	AAACL1069K	Shuban Prints	ABSF52480B	Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence)	Advance		0.00	Approved			0.00	15.08	0.00																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																						

Related party transactions for the period 1 Oct 2024 to 31 Mar 2025														Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
Sr. No.	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments						
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)		
63	Lupin Limited	AAACL1069K	Lupin Australia Pty Limited, Australia	AABCL781SL	Wholly-Owned Subsidiary	Any other transaction	Expts Payable	0.00	Approved			0.00	19.10	22.51											
64	Lupin Limited	AAACL1069K	Generic Health Pty Limited, Australia	AADCG8411F	Wholly-Owned Subsidiary	Any other transaction	Expts Reimbursed	4.47	Approved			4.47	0.00	0.00											
65	Lupin Limited	AAACL1069K	Hormosan Pharma GmbH, Germany	AACCH4950M	Wholly-Owned Subsidiary	Any other transaction	Expts Reimbursed	12.48	Approved			12.48	0.00	0.00											
66	Lupin Limited	AAACL1069K	Laboratorios Grin, S.A. de C.V., Mexico	ZZZZ29999Z	Wholly-Owned Subsidiary	Any other transaction	Expts Reimbursed	0.10	Approved			0.10	0.00	0.00											
67	Lupin Limited	AAACL1069K	Lupin Atlantis Holdings SA, Switzerland	AABCL8673N	Wholly-Owned Subsidiary	Any other transaction	Expts Reimbursed	0.02	Approved			0.02	0.00	0.00											
68	Lupin Limited	AAACL1069K	Lupin Australia Pty Limited, Australia	AABCL781SL	Wholly-Owned Subsidiary	Any other transaction	Expts Reimbursed	7.99	Approved			7.99	0.00	0.00											
69	Lupin Limited	AAACL1069K	Lupin Diagnostics Limited, India	AABCL9756A	Wholly-Owned Subsidiary	Any other transaction	Expts Reimbursed	2.12	Approved			2.12	0.00	0.00											
70	Lupin Limited	AAACL1069K	Lupin Europe GmbH, Germany	ZZZZ29999Z	Wholly-Owned Subsidiary	Any other transaction	Expts Reimbursed	117.02	Approved			117.02	0.00	0.00											
71	Lupin Limited	AAACL1069K	Lupin Inc., USA	ZZZZ29999Z	Wholly-Owned Subsidiary	Any other transaction	Expts Reimbursed	70.29	Approved			70.29	0.00	0.00											
72	Lupin Limited	AAACL1069K	Lupin Investments Pvt. Limited	AAACL1070G	Entity having significant influence over the company	Any other transaction	Expts Reimbursed	0.01	Approved			0.01	0.00	0.00											
73	Lupin Limited	AAACL1069K	Lupin Manufacturing Solutions Limited, India	AAFCL4868F	Wholly-Owned Subsidiary	Any other transaction	Expts Reimbursed	32.17	Approved			32.17	0.00	0.00											
74	Lupin Limited	AAACL1069K	Lupin NZ Ltd., New Zealand	ZZZZ29999Z	Subsidiary	Any other transaction	Expts Reimbursed	1.51	Approved			1.51	0.00	0.00											
75	Lupin Limited	AAACL1069K	Lupin Pharma Canada Limited, Canada	AABCL8600M	Wholly-Owned Subsidiary	Any other transaction	Expts Reimbursed	24.36	Approved			24.36	0.00	0.00											
76	Lupin Limited	AAACL1069K	Lupin Pharmaceuticals, Inc., USA	AABCL8374L	Wholly-Owned Subsidiary	Any other transaction	Expts Reimbursed	572.96	Approved			572.96	0.00	0.00											
77	Lupin Limited	AAACL1069K	Lupin Research Inc., USA	AAACL4563B	Wholly-Owned Subsidiary	Any other transaction	Expts Reimbursed	0.06	Approved			0.06	0.00	0.00											
78	Lupin Limited	AAACL1069K	Novel Laboratories, Inc., USA	AAGCN0888A	Wholly-Owned Subsidiary	Any other transaction	Expts Reimbursed	0.17	Approved			0.17	0.00	0.00											
79	Lupin Limited	AAACL1069K	Lupin Pharmaceuticals, Inc., USA	AABCL8374L	Wholly-Owned Subsidiary	Any other transaction	Guarantee Fees Income	35.16	Approved			35.16	0.00	0.00											
80	Lupin Limited	AAACL1069K	Medquimica Industria Farmaceutica LTDA, Brazil	ZZZZ29999Z	Wholly-Owned Subsidiary	Any other transaction	Guarantee Fees Income	7.05	Approved			7.05	0.00	0.00											
81	Lupin Limited	AAACL1069K	Nanoni B.V., Netherlands	AABCL8598G	Wholly-Owned Subsidiary	Any other transaction	Guarantee Fees Income	21.44	Approved			21.44	0.00	0.00											
82	Lupin Limited	AAACL1069K	Generic Health Pty Limited, Australia	AADCG8411F	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	2.58	6.30											
83	Lupin Limited	AAACL1069K	Hormosan Pharma GmbH, Germany	AACCH4950M	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	1.56	1.49											
84	Lupin Limited	AAACL1069K	Lupin Atlantis Holdings SA, Switzerland	AABCL8673N	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	15.36	17.21											
85	Lupin Limited	AAACL1069K	Lupin Australia Pty Limited, Australia	AABCL781SL	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	0.17	0.12											
86	Lupin Limited	AAACL1069K	Lupin Diagnostics Limited, India	AABCL9756A	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	5.64	3.86											
87	Lupin Limited	AAACL1069K	Lupin Digital Health Limited, India	AACL6230G	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	1.20	0.67											
88	Lupin Limited	AAACL1069K	Lupin Europe GmbH, Germany	ZZZZ29999Z	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	0.23	0.21											
89	Lupin Limited	AAACL1069K	Lupin Healthcare (UK) Limited, UK	AABCL7447E	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	1.33	1.18											
90	Lupin Limited	AAACL1069K	Lupin Inc., USA	ZZZZ29999Z	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	118.86	111.65											
91	Lupin Limited	AAACL1069K	Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited)	AAFCL4799H	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	1101.11	35.84											
92	Lupin Limited	AAACL1069K	Lupin Management, Inc., USA	AAELC2971J	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	0.98	0.82											
93	Lupin Limited	AAACL1069K	Lupin Manufacturing Solutions Limited, India	AAFCL4868F	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	118.04	109.90											
94	Lupin Limited	AAACL1069K	Lupin NZ Ltd., New Zealand	ZZZZ29999Z	Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	0.00	0.13											
95	Lupin Limited	AAACL1069K	Lupin Oncology Inc., USA	ZZZZ29999Z	Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	100.11	184.40											
96	Lupin Limited	AAACL1069K	Lupin Pharma Canada Limited, Canada	AABCL8600M	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	1.51	1.74											
97	Lupin Limited	AAACL1069K	Lupin Pharmaceuticals, Inc., USA	AABCL8374L	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	27.24	25.01											
98	Lupin Limited	AAACL1069K	Lupin Philippines, Inc., Philippines	ZZZZ29999Z	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	0.58	0.49											
99	Lupin Limited	AAACL1069K	Lupin Research Inc., USA	AAACL4563B	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	2.33	2.02											
100	Lupin Limited	AAACL1069K	Medquimica Industria Farmaceutica LTDA, Brazil	ZZZZ29999Z	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	3.91	7.05											
101	Lupin Limited	AAACL1069K	Multicare Pharmaceuticals Philippines, Inc., Philippines	AAGCH7842M	Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	1.66	1.33											
102	Lupin Limited	AAACL1069K	Nanoni B.V., Netherlands	AABCL8598G	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	11.37	11.26											
103	Lupin Limited	AAACL1069K	Novel Laboratories, Inc., USA	AACCH0888A	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	2.39	1.78											
104	Lupin Limited	AAACL1069K	Pharma Dynamics (Proprietary) Limited, South Africa	AAFPC6771K	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	3.56	3.50											
105	Lupin Limited	AAACL1069K	Southern Cross Pharma Pty Ltd., Australia	ZZZZ29999Z	Wholly-Owned Subsidiary	Any other transaction	Income Receivable	0.00	Approved			0.00	0.20	0.27											
106	Lupin Limited	AAACL1069K	Lupin Diagnostics Limited, India	AABCL9756A	Wholly-Owned Subsidiary	Interest received		0.06	Approved			0.06	0.00	0.00											
107	Lupin Limited	AAACL1069K	Lupin Digital Health Limited, India	AACL6230G	Wholly-Owned Subsidiary	Interest received		0.00	Approved			0.00	0.00	0.00											
108	Lupin Limited	AAACL1069K	Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited)	AAFCL4799H	Wholly-Owned Subsidiary	Interest received		39.40	Approved			39.40	0.00	0.00											
109	Lupin Limited	AAACL1069K	Lupin Manufacturing Solutions Limited, India	AAFCL4868F	Wholly-Owned Subsidiary	Interest received		9.51	Approved			9.51	0.00	0.00											
110	Lupin Limited	AAACL1069K	Lupin Diagnostics Limited, India	AABCL9756A	Wholly-Owned Subsidiary	Investment		500.00	Approved			500.00	0.00	0.00											
111	Lupin Limited	AAACL1069K	Lupin Digital Health Limited, India	AACL6230G	Wholly-Owned Subsidiary	Investment		248.10	Approved			248.10	0.00	0.00											

Related party transactions for the period 1 Oct 2024 to 31 Mar 2025														Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
Sr. No.	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Details of the loans, inter-corporate deposits, advances or investments					
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)		
140	Lupin Limited	AAACL1069K	Lupin Healthcare (UK) Limited, UK	AAACL7447E	Wholly-Owned Subsidiary	Any other transaction	Recoveries	8.15	Approved			8.15	0.00	0.00											
141	Lupin Limited	AAACL1069K	Lupin Human Welfare and Research Foundation	AAATL0462B	Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence)	Any other transaction	Recoveries	1.62	Approved			1.62	0.00	0.00											
142	Lupin Limited	AAACL1069K	Lupin Inc., USA	ZZZZ2999Z	Wholly-Owned Subsidiary	Any other transaction	Recoveries	20.87	Approved			20.87	0.00	0.00											
143	Lupin Limited	AAACL1069K	Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited)	AAFLC4799M	Wholly-Owned Subsidiary	Any other transaction	Recoveries	9.58	Approved			9.58	0.00	0.00											
144	Lupin Limited	AAACL1069K	Lupin Management, Inc., USA	AAECL2971J	Wholly-Owned Subsidiary	Any other transaction	Recoveries	106.85	Approved			106.85	0.00	0.00											
145	Lupin Limited	AAACL1069K	Lupin Manufacturing Solutions Limited, India	AAFLC4868F	Wholly-Owned Subsidiary	Any other transaction	Recoveries	36.29	Approved			36.29	0.00	0.00											
146	Lupin Limited	AAACL1069K	Lupin Pharma Canada Limited, Canada	AAACL8600M	Wholly-Owned Subsidiary	Any other transaction	Recoveries	4.29	Approved			4.29	0.00	0.00											
147	Lupin Limited	AAACL1069K	Lupin Pharmaceuticals, Inc., USA	AAACL8374L	Wholly-Owned Subsidiary	Any other transaction	Recoveries	134.44	Approved			134.44	0.00	0.00											
148	Lupin Limited	AAACL1069K	Lupin Philipines, Inc., Philipines	ZZZZ2999Z	Wholly-Owned Subsidiary	Any other transaction	Recoveries	0.01	Approved			0.01	0.00	0.00											
149	Lupin Limited	AAACL1069K	Lupin Research Inc., USA	AAACL4563B	Wholly-Owned Subsidiary	Any other transaction	Recoveries	4.51	Approved			4.51	0.00	0.00											
150	Lupin Limited	AAACL1069K	Medquimica Industria Farmaceutica LTDA, Brazil	ZZZZ2999Z	Wholly-Owned Subsidiary	Any other transaction	Recoveries	6.51	Approved			6.51	0.00	0.00											
151	Lupin Limited	AAACL1069K	Multicare Pharmaceuticals Philipines, Inc., Philipines	AAOCM7842M	Subsidiary	Any other transaction	Recoveries	4.50	Approved			4.50	0.00	0.00											
152	Lupin Limited	AAACL1069K	Nanomi B.V., Netherlands	AAACL8598G	Wholly-Owned Subsidiary	Any other transaction	Recoveries	1.58	Approved			1.58	0.00	0.00											
153	Lupin Limited	AAACL1069K	Novel Laboratories, Inc., USA	AAACN0888A	Wholly-Owned Subsidiary	Any other transaction	Recoveries	3.93	Approved			3.93	0.00	0.00											
154	Lupin Limited	AAACL1069K	Pharma Dynamics (Proprietary) Limited, South Africa	AAFCP6771K	Wholly-Owned Subsidiary	Any other transaction	Recoveries	6.58	Approved			6.58	0.00	0.00											
155	Lupin Limited	AAACL1069K	Polynova Industries Limited	AAACP3071F	Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence)	Any other transaction	Recoveries	0.12	Approved			0.12	0.00	0.00											
156	Lupin Limited	AAACL1069K	Dr. Punita Kumar-Sinha	DAKPS7631M	Non- Executive Directors	Remuneration		11.65	Approved			11.65	0.00	0.00											
157	Lupin Limited	AAACL1069K	Mr. Alfonso Zulueta	ZZZZ2999Z	Non- Executive Directors	Remuneration		14.34	Approved			14.34	0.00	0.00											
158	Lupin Limited	AAACL1069K	Mr. Amit Kumar Gupta	AAFCPS3487E	Key Management Personnel	Remuneration		4.81	Approved			4.81	0.00	0.00											
159	Lupin Limited	AAACL1069K	Mr. Jean-Luc Belingard	GSYPB2716A	Non- Executive Directors	Remuneration		14.45	Approved			14.45	0.00	0.00											
160	Lupin Limited	AAACL1069K	Mr. Jeffrey Kindler	ZZZZ2999Z	Non- Executive Directors	Remuneration		14.50	Approved			14.50	0.00	0.00											
161	Lupin Limited	AAACL1069K	Mr. K. B. S. Anand	AABPA6586A	Non- Executive Directors	Remuneration		10.91	Approved			10.91	0.00	0.00											
162	Lupin Limited	AAACL1069K	Mr. Mark D. McDade	QGSFH0067D	Non- Executive Directors	Remuneration		14.86	Approved			14.86	0.00	0.00											
163	Lupin Limited	AAACL1069K	Mr. Nilesh D. Gupta	AAFCP0883F	Key Management Personnel	Remuneration		55.60	Approved			55.60	0.00	0.00											
164	Lupin Limited	AAACL1069K	Mr. R. V. Satam	AAWPS4559C	Key Management Personnel	Remuneration		-4.82	Approved			-4.82	0.00	0.00											
165	Lupin Limited	AAACL1069K	Mr. Ramesh Swaminathan	AACPR1353H	Key Management Personnel	Remuneration		57.16	Approved			57.16	0.00	0.00											
166	Lupin Limited	AAACL1069K	Mrs. Manju D. Gupta	AABPG2862M	Non- Executive Directors	Remuneration		5.25	Approved			5.25	0.00	0.00											
167	Lupin Limited	AAACL1069K	Ms. Vinita Gupta	AAEPG1031H	Key Management Personnel	Remuneration		147.26	Approved			147.26	0.00	0.00											
168	Lupin Limited	AAACL1069K	Zyma Properties Pvt. Limited	AAFCV8237J	Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence)	Any other transaction	Rent Expense	6.00	Approved			6.00	0.00	0.00											
169	Lupin Limited	AAACL1069K	Lupin Digital Health Limited, India	AAECL6230G	Wholly-Owned Subsidiary	Any other transaction	Rent Income	3.00	Approved			3.00	0.00	0.00											
170	Lupin Limited	AAACL1069K	Lupin Manufacturing Solutions Limited, India	AAFLC4868F	Wholly-Owned Subsidiary	Any other transaction	Rent Income	8.05	Approved			8.05	0.00	0.00											
171	Lupin Limited	AAACL1069K	Polynova Industries Limited	AAACP3071F	Others (Relatives of KMP and Entities in which the KMP and Relatives of KMP have control or significant influence)	Any other transaction	Rent Income	0.81	Approved			0.81	0.00	0.00											
172	Lupin Limited	AAACL1069K	Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited)	AAFLC4799M	Wholly-Owned Subsidiary	Sale of goods or services		2.11	Approved			2.11	0.00	0.00											
173	Lupin Limited	AAACL1069K	Medquimica Industria Farmaceutica LTDA, Brazil	ZZZZ2999Z	Wholly-Owned Subsidiary	Sale of goods or services		1.60	Approved			1.60	0.00	0.00											
174	Lupin Limited	AAACL1069K	Lupin Atlantis Holdings SA, Switzerland	AAACL8673N	Wholly-Owned Subsidiary	Sale of goods or services		27.67	Approved			27.67	0.00	0.00											
175	Lupin Limited	AAACL1069K	Lupin Inc., USA	ZZZZ2999Z	Wholly-Owned Subsidiary	Sale of goods or services		256.93	Approved			256.93	0.00	0.00											
176	Lupin Limited	AAACL1069K	Lupin Manufacturing Solutions Limited, India	AAFLC4868F	Wholly-Owned Subsidiary	Sale of goods or services		313.49	Approved			313.49	0.00	0.00											
177	Lupin Limited	AAACL1069K	Lupin Oncology Inc., USA	ZZZZ2999Z	Subsidiary	Sale of goods or services		302.34	Approved			302.34	0.00	0.00											
178	Lupin Limited	AAACL1069K	Lupin Research Inc., USA	AAACL4563B	Wholly-Owned Subsidiary	Sale of goods or services		1.16	Approved			1.16	0.00	0.00											
179	Lupin Limited	AAACL1069K	Generic Health Pty Limited, Australia	AADCG8411F	Wholly-Owned Subsidiary	Sale of goods or services		468.96	Approved			468.96	0.00	0.00											
180	Lupin Limited	AAACL1069K	Hormosan Pharma GmbH, Germany	AAACH4950M	Wholly-Owned Subsidiary	Sale of goods or services		439.88	Approved			439.88	0.00	0.00											
181	Lupin Limited	AAACL1069K	Lupin Atlantis Holdings SA, Switzerland	AAACL8673N	Wholly-Owned Subsidiary	Sale of goods or services		479.94	Approved			479.94	0.00	0.00											
182	Lupin Limited	AAACL1069K	Lupin Healthcare (UK) Limited, UK	AAACL7447E	Wholly-Owned Subsidiary	Sale of goods or services		2156.34	Approved			2156.34	0.00	0.00											
183	Lupin Limited	AAACL1069K	Lupin Inc., USA	ZZZZ2999Z	Wholly-Owned Subsidiary	Sale of goods or services		5089.46	Approved			5089.46	0.00	0.00											
184	Lupin Limited	AAACL1069K	Lupin Life Sciences Limited, India (formerly known as Lupin Atharv Ability Limited)	AAFLC4799M	Wholly-Owned Subsidiary	Sale of goods or services		17.25	Approved			17.25	0.00	0.00											
185	Lupin Limited	AAACL1069K	Lupin Manufacturing Solutions Limited, India	AAFLC4868F	Wholly-Owned Subsidiary	Sale of goods or services		43.76	Approved			43.76	0.00	0.00											
186	Lupin Limited	AAACL1069K	Lupin Pharma Canada Limited, Canada	AAACL8600M	Wholly-Owned Subsidiary	Sale of goods or services		-3.30	Approved			-3.30	0.00	0.00											
187	Lupin Limited	AAACL1069K	Lupin Pharmaceuticals, Inc., USA	AAACL8374L	Wholly-Owned Subsidiary	Sale of goods or services		26906.27	Approved			26906.27	0.00	0.00											
188	Lupin Limited	AAACL1069K	Lupin Philipines, Inc., Philipines	ZZZZ2999Z	Wholly-Owned Subsidiary	Sale of goods or services		12																	

Related party transactions for the period 1 Oct 2024 to 31 Mar 2025													Additional disclosure of related party transactions - applicable only in case the related party transaction relates to										
---	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Related party transactions for the period 1 Oct 2024 to 31 Mar 2025																										
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction	In case any financial indebtedness is incurred to make or give loans, inter- corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.						Details of the loans, inter- corporate deposits, advances or investments						
Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Not			
265	Lupin Atlantis Holdings SA, Switzerland	AABCL8673N	Lupin Inc., USA	ZZZZZ9999Z	Fellow Subsidiary	Investment		0.00	Not Applicable			-23464.28	23464.28	0.00												
266	Lupin Atlantis Holdings SA, Switzerland	AABCL8673N	Lymed S.A.S., France	ZZZZZ9999Z	Fellow Subsidiary	Investment		0.00	Not Applicable			0.00	917.01	917.01												
267	Lupin Atlantis Holdings SA, Switzerland	AABCL8673N	Medisol S.A.S., France	ZZZZZ9999Z	Fellow Subsidiary	Investment		0.00	Not Applicable			0.00	917.01	917.01												
268	Lupin Atlantis Holdings SA, Switzerland	AABCL8673N	Laboratorios Grin, S.A. de C.V., Mexico	ZZZZZ9999Z	Fellow Subsidiary	Loan		0.00	Not Applicable			98.32	782.37	684.05				Loan	5.00%	9 yrs	Unsecured	Business Purpose				
269	Lupin Atlantis Holdings SA, Switzerland	AABCL8673N	Laboratorios Grin, S.A. de C.V., Mexico	ZZZZZ9999Z	Fellow Subsidiary	Any other transaction	Income Receivable	0.00	Not Applicable			0.00	11.35	8.68				Loan	5.00%	9 yrs	Unsecured	Business Purpose				
270	Lupin Atlantis Holdings SA, Switzerland	AABCL8673N	Lupin Healthcare (UK) Limited, UK	AABCL7447E	Fellow Subsidiary	Loan		0.00	Not Applicable			1201.55	897.95	2099.50				Loan	5.50%	2 yrs	Unsecured	Business Purpose				
271	Lupin Atlantis Holdings SA, Switzerland	AABCL8673N	Nanomi B.V., Netherlands	AABCL8598G	Fellow Subsidiary	Loan		0.00	Not Applicable			36.56	1843.62	1880.19				Loan	3.75%	3 yrs	Unsecured	Business Purpose				
272	Lupin Atlantis Holdings SA, Switzerland	AABCL8673N	Medquimica Industria Farmaceutica LTDA, Brazil	ZZZZZ9999Z	Fellow Subsidiary	Loan		0.00	Not Applicable			-462.22	1759.82	2222.04				Loan	4.50%	3 yrs	Unsecured	Business Purpose				
273	Lupin Atlantis Holdings SA, Switzerland	AABCL8673N	Medquimica Industria Farmaceutica LTDA, Brazil	ZZZZZ9999Z	Fellow Subsidiary	Any other transaction	Income Receivable	0.00	Not Applicable			0.00	11.79	14.90				Loan	4.50%	3 yrs	Unsecured	Business Purpose				
274	Lupin Atlantis Holdings SA, Switzerland	AABCL8673N	Laboratorios Grin, S.A. de C.V., Mexico	ZZZZZ9999Z	Fellow Subsidiary	Interest received		0.00	Not Applicable			18.94	0.00	0.00												
275	Lupin Atlantis Holdings SA, Switzerland	AABCL8673N	Lupin Healthcare (UK) Limited, UK	AABCL7447E	Fellow Subsidiary	Interest received		0.00	Not Applicable			27.50	0.00	0.00												
276	Lupin Atlantis Holdings SA, Switzerland	AABCL8673N	Nanomi B.V., Netherlands	AABCL8598G	Fellow Subsidiary	Interest received		0.00	Not Applicable			39.65	0.00	0.00												
277	Lupin Atlantis Holdings SA, Switzerland	AABCL8673N	Medquimica Industria Farmaceutica LTDA, Brazil	ZZZZZ9999Z	Fellow Subsidiary	Interest received																				

Related party transactions for the period 1 Oct 2024 to 31 Mar 2025														Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
Sr. No.	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments										
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)		
321	Lupin Manufacturing Solutions Limited, India	AAFL4868F	Medquimica Industria Farmaceutica LTDA, Brazil	ZZZZ9999Z	Fellow Subsidiary	Any other transaction	Trade Receivables	0.00	Not Applicable			0.00	4.13	41.03											
322	Lupin Manufacturing Solutions Limited, India	AAFL4868F	Lupin Healthcare (UK) Limited, UK	AA8CL7447E	Fellow Subsidiary	Purchase of goods or services		0.00	Not Applicable			12.98	0.00	0.00											
323	Lupin Manufacturing Solutions Limited, India	AAFL4868F	Lupin Healthcare (UK) Limited, UK	AA8CL7447E	Fellow Subsidiary	Any other transaction	Trade Payables	0.00	Not Applicable			0.00	0.00	12.98											
324	Generic Health Pty Limited, Australia	AADCG8411F	Southern Cross Pharma Pty Ltd., Australia	ZZZZ9999Z	Fellow Subsidiary	Investment		0.00	Not Applicable			0.00	1665.95	1665.95											
325	Generic Health Pty Limited, Australia	AADCG8411F	Lupin Australia Pty Limited, Australia	AA8CL7815L	Fellow Subsidiary	Purchase of goods or services		0.00	Not Applicable			0.05	0.00	0.00											
326	Generic Health Pty Limited, Australia	AADCG8411F	Southern Cross Pharma Pty Ltd., Australia	ZZZZ9999Z	Fellow Subsidiary	Purchase of goods or services		0.00	Not Applicable			112.24	0.00	0.00											
327	Generic Health Pty Limited, Australia	AADCG8411F	Lupin Australia Pty Limited, Australia	AA8CL7815L	Fellow Subsidiary	Any other transaction	Reimbursement	0.00	Not Applicable			0.05	0.00	0.00											
328	Generic Health Pty Limited, Australia	AADCG8411F	Southern Cross Pharma Pty Ltd., Australia	ZZZZ9999Z	Fellow Subsidiary	Any other transaction	Recoveries	0.00	Not Applicable			0.39	0.00	0.00											
329	Generic Health Pty Limited, Australia	AADCG8411F	Lupin Australia Pty Limited, Australia	AA8CL7815L	Fellow Subsidiary	Any other transaction	Recoveries	0.00	Not Applicable			0.04	0.00	0.00											
330	Generic Health Pty Limited, Australia	AADCG8411F	Lupin NZ Ltd., New Zealand	ZZZZ9999Z	Fellow Subsidiary	Any other transaction	Recoveries	0.00	Not Applicable			0.25	0.00	0.00											
331	Generic Health Pty Limited, Australia	AADCG8411F	Lupin Australia Pty Limited, Australia	AA8CL7815L	Fellow Subsidiary	Loan		0.00	Not Applicable			0.00	20.21	21.16				Loan	0.00%	1	Unsecured	Business purpose			
332	Generic Health Pty Limited, Australia	AADCG8411F	Southern Cross Pharma Pty Ltd., Australia	ZZZZ9999Z	Fellow Subsidiary	Loan		0.00	Not Applicable			0.00	499.08	142.04				Loan	0.00%	1	Unsecured	Business purpose			
333	Generic Health Pty Limited, Australia	AADCG8411F	Lupin NZ Ltd., New Zealand	ZZZZ9999Z	Fellow Subsidiary	Loan		0.00	Not Applicable			0.00	0.00	5.02											
334	Generic Health Pty Limited, Australia	AADCG8411F	Lupin Australia Pty Limited, Australia	AA8CL7815L	Fellow Subsidiary	Any other transaction	Trade Receivable	0.00	Not Applicable			0.00	0.00	0.00											
335	Generic Health Pty Limited, Australia	AADCG8411F	Lupin Australia Pty Limited, Australia	AA8CL7815L	Fellow Subsidiary	Any other transaction	Trade Payable	0.00	Not Applicable			0.00	0.25	0.03											
336	Generic Health Pty Limited, Australia	AADCG8411F	Southern Cross Pharma Pty Ltd., Australia	ZZZZ9999Z	Fellow Subsidiary	Any other transaction	Trade Receivable	0.00	Not Applicable			0.00	0.17	0.00											
337	Generic Health Pty Limited, Australia	AADCG8411F	Lupin NZ Ltd., New Zealand	ZZZZ9999Z	Fellow Subsidiary	Any other transaction	Trade Receivable	0.00	Not Applicable			0.00	0.00	0.24											
338	Generic Health Pty Limited, Australia	AADCG8411F	Southern Cross Pharma Pty Ltd., Australia	ZZZZ9999Z	Fellow Subsidiary	Any other transaction	Trade Payable	0.00	Not Applicable			0.00	23.58	36.09											
339	Lupin Diagnostics Limited, India	AA8CL9756A	Lupin Digital Health Limited, India	AA8CL6230G	Fellow Subsidiary	Any other transaction	Expenses incurred on our behalf reimbursed & Other Reimbursements	0.00	Not Applicable			0.01	0.00	0.00											
340	Multicare Pharmaceuticals Philippines, Inc., Philippines	AAGCM7842M	Lupin Philippines, Inc., Philippines	ZZZZ9999Z	Fellow Subsidiary	Any other transaction	Rent Income	0.00	Not Applicable			0.31	0.00	0.00											
341	Multicare Pharmaceuticals Philippines, Inc., Philippines	AAGCM7842M	Lupin Philippines, Inc., Philippines	ZZZZ9999Z	Fellow Subsidiary	Sale of fixed assets		0.00	Not Applicable			0.30	0.00	0.00											
342	Multicare Pharmaceuticals Philippines, Inc., Philippines	AAGCM7842M	Lupin Philippines, Inc., Philippines	ZZZZ9999Z	Fellow Subsidiary	Any other transaction	Expenses incurred on our behalf reimbursed & Other Reimbursements	0.00	Not Applicable			0.02	0.00	0.00											
343	Multicare Pharmaceuticals Philippines, Inc., Philippines	AAGCM7842M	Lupin Philippines, Inc., Philippines	ZZZZ9999Z	Fellow Subsidiary	Purchase of goods or services		0.00	Not Applicable			161.21	0.00	0.00											
344	Multicare Pharmaceuticals Philippines, Inc., Philippines	AAGCM7842M	Lupin Philippines, Inc., Philippines	ZZZZ9999Z	Fellow Subsidiary	Any other transaction	Payables	0.00	Not Applicable			0.00	895.49	786.50											
345	Multicare Pharmaceuticals Philippines, Inc., Philippines	AAGCM7842M	Lupin Philippines, Inc., Philippines	ZZZZ9999Z	Fellow Subsidiary	Any other transaction	Receivables	0.00	Not Applicable			0.00	0.05	0.07											
346	Multicare Pharmaceuticals Philippines, Inc., Philippines	AAGCM7842M	Laboratorios Grin, S.A. de C.V., Mexico	ZZZZ9999Z	Fellow Subsidiary	Purchase of goods or services		0.00	Not Applicable			0.23	0.00	0.00											
347	Lupin Pharmaceuticals, Inc., USA	AA8CL8374L	Lupin Inc., USA	ZZZZ9999Z	Fellow Subsidiary	Any other transaction	Product Liability	0.00	Not Applicable			19.18	0.00	0.00											
348	Lupin Pharmaceuticals, Inc., USA	AA8CL8374L	Lupin Inc., USA	ZZZZ9999Z	Fellow Subsidiary	Sale of goods or services		0.00	Not Applicable			110.00	0.00	0.00											
349	Lupin Pharmaceuticals, Inc., USA	AA8CL8374L	Lupin Inc., USA	ZZZZ9999Z	Fellow Subsidiary	Sale of goods or services		0.00	Not Applicable			25.14	0.00	0.00											
350	Lupin Pharmaceuticals, Inc., USA	AA8CL8374L	Lupin Inc., USA	ZZZZ9999Z	Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	0.00	Not Applicable			80.32	0.00	0.00											
351	Lupin Pharmaceuticals, Inc., USA	AA8CL8374L	Lupin Management, Inc., USA	AA8CL2971J	Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	0.00	Not Applicable			5.44	0.00	0.00											
352	Lupin Pharmaceuticals, Inc., USA	AA8CL8374L	Lupin Manufacturing Solutions Limited, India	AAFL4868F	Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	0.00	Not Applicable			8.04	0.00	0.00											
353	Lupin Pharmaceuticals, Inc., USA	AA8CL8374L	Lupin Research Inc., USA	AA8CL4563B	Fellow Subsidiary	Sale of goods or services		0.00	Not Applicable			0.45	0.00	0.00											
354	Lupin Pharmaceuticals, Inc., USA	AA8CL8374L	Lupin Research Inc., USA	AA8CL4563B	Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	0.00	Not Applicable			19.75	0.00	0.00											
355	Lupin Pharmaceuticals, Inc., USA	AA8CL8374L	Medquimica Industria Farmaceutica LTDA, Brazil	ZZZZ9999Z	Fellow Subsidiary	Any other transaction	Expenses incurred on our behalf reimbursed & Other Reimbursements	0.00	Not Applicable			0.02	0.00	0.00											
356	Lupin Pharmaceuticals, Inc., USA	AA8CL8374L	Novel Laboratories, Inc., USA	AAGCN0888A	Fellow Subsidiary	Sale of goods or services		0.00	Not Applicable			4.24	0.00	0.00											
357	Lupin Pharmaceuticals, Inc., USA	AA8CL8374L	Novel Laboratories, Inc., USA	AAGCN0888A	Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	0.00	Not Applicable			192.09	0.00	0.00											
358	Lupin Research Inc., USA	AA8CL4563B	Lupin Healthcare (UK) Limited, UK	AA8CL7447E	Fellow Subsidiary	Any other transaction	Expenses incurred on our behalf reimbursed & Other Reimbursements	0.00	Not Applicable			54.63	0.00	0.00											
359	Lupin Research Inc., USA	AA8CL4563B	Lupin Inc., USA	ZZZZ9999Z	Fellow Subsidiary	Sale of goods or services		0.00	Not Applicable			1868.17	0.00	0.00											
360	Lupin Research Inc., USA	AA8CL4563B	Lupin Inc., USA	ZZZZ9999Z	Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	0.00	Not Applicable			28.58	0.00	0.00											
361	Lupin Research Inc., USA	AA8CL4563B	Lupin Management, Inc., USA	AA8CL2971J	Fellow Subsidiary	Sale of goods or services		0.00	Not Applicable			5.17	0.00	0.00											
362	Lupin Research Inc., USA	AA8CL4563B	Lupin Pharmaceuticals, Inc., USA	AA8CL8374L	Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	0.00	Not Applicable			1.61	0.00	0.00											
363	Lupin Research Inc., USA	AA8CL4563B	Nanomi B.V., Netherlands	AA8CL8598G	Fellow Subsidiary	Sale of goods or services		0.00	Not Applicable			0.61	0.00	0.00											
364	Novel Laboratories, Inc., USA	AAGCN0888A	Lupin Inc., USA	ZZZZ9999Z	Fellow Subsidiary	Sale of goods or services		0.00	Not Applicable			783.48	0.00	0.00											
365	Novel Laboratories, Inc., USA	AAGCN0888A	Lupin Inc., USA	ZZZZ9999Z	Fellow Subsidiary	Sale of goods or services		0.00	Not Applicable			2737.97	0.00	0.00											
366	Novel Laboratories, Inc., USA	AAGCN0888A	Lupin Inc., USA	ZZZZ9999Z	Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	0.00	Not Applicable			14.10	0.00	0.00											
367	Novel Laboratories, Inc., USA	AAGCN0888A	Lupin Pharmaceuticals, Inc., USA	AA8CL8374L	Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	0.00	Not Applicable			39.76	0.00	0.00											
368	Novel Laboratories, Inc., USA	AAGCN0888A	Lupin Research Inc., USA	AA8CL4563B	Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	0.00	Not Applicable			0.24	0.00	0.00											



Related party transactions for the period 1 Oct 2024 to 31 Mar 2025

													Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter- corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
Sr. No.	Details of the party (listed entry /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter- corporate deposits, advances or investments							
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
388																						